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AcromegAly consists of a constellation of clinical signs and symptoms caused by an excess produc-tion of GH. The onset of this disease can be quite 
insidious, and common clinical manifestations include 
acral overgrowth, soft tissue hypertrophy, metabolic de-
rangements, and cardiovascular complications.37 While a 
host of pathological entities can cause GH overproduc-
tion, more than 90% of patients with acromegaly harbor 
a GH-secreting pituitary adenoma.49 Although these ade-
nomas arise from the benign proliferation of somatotroph 
cells within the anterior pituitary gland, the pituitary’s 
confined location within the sella turcica and close ap-
proximation to important neurovascular structures render 
masses in this region problematic. Therefore, aside from 
complications secondary to GH excess, patients may also 
experience headache, visual loss, cranial nerve deficits, 
and symptoms of additional pituitary hormone dysregu-
lation.18 
Surgical extirpation of the culprit lesion is consid-
ered first-line treatment and has the distinct advantage of 
instantaneously lowering GH levels by directly remov-
ing the source of hormone production.28 Recent studies 
estimate postoperative endocrinological remission rates 
to be 68% to 95%, irrespective of tumor volume.28,34 De-
spite this clinical efficacy, not only is surgery alone not 
curative in a select cohort of patients, but recurrent acro-
megaly following initial postoperative hormonal remis-
sion is reported to occur in as many as 19% of cases.28 Al-
though regrowth of previously resected tumor has been 
documented,16 these recurrences most likely represent 
continued growth of nonresectable tumor tissue, either 
due to parasellar invasion or involvement of neighboring 
neurovascular structures.18,31,37 Stereotactic radiosurgery 
has emerged as a noninvasive adjuvant treatment modal-
The role of stereotactic radiosurgery in the multimodal  
management of growth hormone–secreting pituitary  
adenomas
Christopher J. stapleton, B.s.,1,2 Charles Y. liu, M.D., ph.D.,1,3  
anD Martin h. Weiss, M.D.1
1Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los 
Angeles, California; 2Harvard-M.I.T. Division of Health Sciences and Technology, Harvard Medical School, 
Boston, Massachusetts; and 3Division of Chemistry and Chemical Engineering, California Institute of  
Technology, Pasadena, California
Growth hormone (GH)–secreting pituitary adenomas represent a common source of GH excess in patients with 
acromegaly. Whereas surgical extirpation of the culprit lesion is considered first-line treatment, as many as 19% of 
patients develop recurrent symptoms due to regrowth of previously resected adenomatous tissue or to continued 
growth of the surgically inaccessible tumor. Although medical therapies that suppress GH production can be effective 
in the management of primary and recurrent acromegaly, these therapies are not curative, and lifelong treatment is 
required for hormonal control. Stereotactic radiosurgery has emerged as an effective adjunctive treatment modality, 
and is an appealing alternative to conventional fractionated radiation therapy. The authors reviewed the growing 
body of literature concerning the role of radiosurgical procedures in the treatment armamentarium of acromegaly, 
and identified more than 1350 patients across 45 case series. In this review, the authors report that radiosurgery offers 
true hormonal normalization in 17% to 82% of patients and tumor growth control in 37% to 100% of cases across 
all series, while minimizing adverse complications. As a result, stereotactic radiosurgery represents a safe and effec-
tive treatment option in the multimodal management of primary or recurrent acromegaly secondary to GH-secreting 
pituitary adenomas. (DOI: 10.3171/2010.7.FOCUS10159)
KeY WorDs      •      acromegaly      •      growth hormone      •      insulin-like growth factor–I      •       
pituitary adenoma      •      radiosurgery
Abbreviations used in this paper: GH = growth hormone; GKS = 
Gamma Knife surgery; IGF = insulin-like growth factor; LINAC = 
linear accelerator; SRS = stereotactic radiosurgery.
C. J. Stapleton, C. Y. Liu, and M. H. Weiss
2                                                                                                                      Neurosurg Focus / Volume 29 / October 2010
ity for such recurrent or surgically inaccessible lesions. 
Unlike conventional fractionated radiotherapy, SRS de-
livers focused radiation to a precisely defined target in a 
single session and minimizes radiation exposure to adja-
cent normal structures.3,29,50 Over the past two decades, 
numerous case series have described the efficacy of SRS 
in patients harboring GH-secreting pituitary adenomas. 
In this report, we review the results from this robust body 
of literature, and highlight postradiosurgical rates of en-
docrinological remission and tumor growth control as 
well as assess the potential advantages and limitations of 
SRS in the multimodal management of acromegaly.
Methods
Data Acquisition
A PubMed search (National Library of Medicine) 
was performed to identify all articles pertaining to the 
use of SRS for the treatment of acromegaly. Surgical se-
ries describing endocrinological and radiographic out-
comes were analyzed in detail and reference lists were re-
viewed for additional articles not identified in the original 
PubMed search. Pertinent clinical characteristics extract-
ed from each report include the stereotactic radiosurgical 
unit; marginal radiation dose; rate of pituitary suppressive 
medication used during SRS; tumor size and prevalence 
of cavernous sinus invasion; rates of endocrinological re-
mission and tumor growth control; and SRS-associated 
complications. Case series utilizing GKS, LINAC-based 
SRS, and CyberKnife radiosurgical systems are included 
in our analysis. Given a variety of confounding factors, 
however, no effort was made to directly compare the ef-
ficacies of these methods of SRS.
Radiosurgical Techniques
Unlike conventional radiotherapy, in which patients 
receive a target dose of radiation to the entire brain frac-
tionated over numerous sessions, radiosurgery aims to 
deliver a high dose of radiation to a precise intracrani-
al region during a single session.27 The ability to focus 
ionizing radiation on discrete brain lesions while spar-
ing critical adjacent neurovascular structures may im-
prove local tumor control as well as reduce the adverse 
effects associated with traditional radiation therapies.51 
The Gamma Knife utilizes cross-firing beams from 201 
cobalt-60 sources to deliver ionizing radiation (gamma 
rays) to an intracranial target. The most commonly used 
radiosurgical unit for pituitary lesions, this system allows 
for a high degree of 3D conformity between the radiation 
field and the target of interest and offers better preserva-
tion of surrounding normal structures than conventional 
radiotherapy.18,19 Similar to the Gamma Knife, LINAC-
based systems deliver beams of photon radiation in mul-
tiple arcs to a defined intracranial structure,50 and allow 
neurosurgeons to target lesions with a high degree of fi-
delity and to minimize the extent of collateral damage to 
surrounding neurovascular elements. 
Both the Gamma Knife and traditional LINAC-based 
systems require the use of a stereotactic frame for rigid 
immobilization of the head during the radiosurgical pro-
cedure. The CyberKnife is a newly developed LINAC-
based system that uses image guidance software to adjust 
in real-time the precise location of radiation therapy and, 
thus, does not require the use of a stereotactic frame.1 Ir-
respective of the radiosurgical unit employed, dose selec-
tion and treatment parameters vary depending on the tu-
mor location and size, relationship of the adenoma to the 
optic apparatus and other eloquent structures, dose and 
timing of any pretreatment conventional radiotherapy, 
and other patient-specific characteristics.
Results
Tables 1 and 2 summarize data obtained from case 
series in which stereotactic radiosurgical procedures were 
employed in the multimodal management of GH-secret-
ing pituitary adenomas. Across all series, more than 1350 
patients underwent SRS using either Gamma Knife- or 
LINAC-based systems for the treatment of primary or re-
current acromegaly. The mean duration of endocrinologi-
cal and radiographic follow-up ranged from greater than 
6 months to 100 months. The average tumor volume was 
between 0.9 cm3 and 11.3 cm3 and, where reported, 21% 
to 100% of patients harbored lesions that extended into 
the cavernous sinus. The mean marginal radiation dose 
employed across all series ranged from 14.3 to 34.4 Gy. 
Approximately 71% of patients throughout the series had 
undergone transsphenoidal or transcranial neurosurgical 
resection of their pituitary adenoma prior to radiosurgery, 
while 11% had received antecedent conventional fraction-
ated radiotherapy. Although reported in only half of the 
case series, approximately 75% of patients had discon-
tinued all suppressive medications for more than 6 to 8 
weeks prior to radiosurgery. While the definition of true 
endocrinological remission was quite variable among the 
series, approximately 47% of patients fulfilled the given 
criteria for hormonal remission, and an additional 32% 
achieved endocrinological normalization after radiosur-
gery with adjunctive medical therapy. Compared with 
preradiosurgical volumes, on average more than 97% of 
tumors decreased or remained the same in size at the time 
of the latest follow-up.
Endocrinological Remission and Control
Whereas the precise criteria for characterizing endo-
crinological remission following SRS were inconsistent 
across the case series, the most widely accepted definition 
is a random GH level less than 2 ng/ml or a GH level less 
than 1 ng/ml following an oral glucose tolerance test in ad-
dition to a normal IGF-I level when controlled for age and 
sex.35 Importantly, these measurements are recorded while 
the patient is not taking pituitary suppressive medications. 
If the above criteria are met after radiosurgery with the aid 
of adjunctive medical therapy, the patient is considered to 
have achieved endocrinological control.16 Using the afore-
mentioned strict criteria for hormonal remission, the range 
of endocrinological normalization was 17% to 82%, and an 
additional 4% to 47% of patients achieved hormonal control 
following radiosurgery.2,4,5,14,16,21,33,45–47,53,54,57,58 For instance, 
Pollock et al.45 observed an endocrinological remission rate 
of 67% and Ikeda et al.14 observed normalized hormonal lev-
els in 82% of patients following GKS. Using LINAC-based 
SRS, Voges et al.58 reported a true remission rate of 37.5% 
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TABLE 1: Summary of previously reported case series involving SRS in patients with acromegaly (Part I)*
Authors & Year
SRS 
Unit
No. of 
Patients
Mean FU 
(mos)
Interventions Prior to 
SRS (%)
Off Medication 
During SRS (%)
Mean Marginal  
Radiation Dose (Gy)
Cavernous Sinus 
Invasion (%)
Hayashi et al., 2010 GK 25 36† surg (100) NA 21.8† 100
Iwai et al., 2010 GK 26 84‡ surg (85) 85 20.2 35
Castinetti et al., 20094 GK 43 100 surg (70) 53 NA 21
Cho et al., 2009 CK 6 35 surg (83) NA NA NA
Swords et al., 2009 GK 10 38.5 CRT (100); surg (80) 40 NA NA
Wan et al., 2009 GK 103 67† surg (14)† 100 21.4 NA
Jagannathan et al., 2008 GK 95 57 CRT (5); surg (100) 71 22 35
Losa et al., 2008 GK 83 69‡ CRT (1); surg (100) 76 25 (goal) NA
Pollock et al., 2008 GK 27 47‡ CRT (7); surg (93) 100 20‡ NA
Tinnel et al., 2008 GK 9 35‡ CRT (11); surg (75) 56 NA NA
Pollock et al., 2007 GK 46 63‡ CRT (13); surg (93) 59 20‡ 85
Roberts et al., 2007 CK 9 25 surg (89) 67 21 NA
Vik-Mo et al., 2007 GK 61 66 surg (92) NA 26.5 NA
Jezková et al., 2006 GK 96 54 CRT (11.5); surg (74) 100 32 NA
Voges et al., 2006 LINAC 64 54 CRT (7)†; surg (53)† NA 16.5 89†
Castinetti et al., 2005 GK 82 49.5 CRT (2); surg (77) 49 25.7 89
Kajiwara et al., 2005 CK 2 35† CRT (10)†; surg (48)† NA 14.3† NA
Kobayashi et al., 2005 GK 67 63 CRT (3); surg (73) 37 18.9 NA
Attanasio et al., 2003 GK 30 46‡ CRT (13); surg (90) 60 20‡ NA
Choi et al., 2003 GK 9 42.5† surg (32)† NA 28.5† NA
Jane et al., 2003 GK 64 >18 surg (100) 100 15† NA
Petrovich et al., 2003 GK 6 41 CRT (10)†; surg (95)† NA 15† 96†
Swords et al., 2003 LINAC 13 25‡ CRT (100); surg (77) 23 10 (mode) 67†
Feigl et al., 2002 GK 9 55† surg (100) NA 15† NA
Pollock et al., 2002 GK 26 36†‡ CRT (21)†; surg (86)† 69 20.1† 70†
Ikeda et al., 2001 GK 17 56 surg (100) 100 25 100
Fukuoka et al., 2001 GK 9 42 surg (89) NA 20 100
Izawa et al., 2000 GK 29 >6 surg (37)† NA 22.5† 29
Shin et al., 2000 GK 6 43 surg (67) 100 34.4 100
Zhang et al., 2000 GK 68 34 CRT (4); surg (14) 100 31.3 NA
Hayashi et al., 1999 GK 22 16 surg (49)† NA 22.5 24
Inoue et al., 1999 GK 12 >24 surg (100) 100 20.9 100
Kim et al., 199923 GK 2 12†‡ none 100 22† NA
Kim et al., 199924 GK 11 27† surg (55) NA 28.7† NA
Laws & Vance, 1999 GK 56 NA NA NA NA NA
Mokry et al., 1999 GK 10 46 CRT (4)†; surg (96)† NA 16 NA
Landolt et al., 1998 GK 16 >17 CRT (44); surg (100) 69 25 NA
Lim et al., 1998 GK 16 25.5† CRT (2)†; surg (51)† NA 25.4† 22†
Martínez et al., 1998 GK 7 36† surg (57) NA 24.7 57
Mitsumori et al., 1998 LINAC 1 47 CRT (22)† NA NA 61†
Morange-Ramos et al., 1998 GK 15 20† CRT (7); surg (87) NA 28.7 76†
Pan et al., 1998 GK 16 29† CRT (4)†; surg (16)† NA 28.6 NA
Witt et al., 1998 GK 20 32 NA NA 19 NA
Yoon et al., 1998 LINAC 2 49† surg (96)† NA NA NA
Park et al., 1996 GK 7 15† surg (14) NA 27.1† NA
* CK = CyberKnife; CRT = conventional radiotherapy; FU = follow-up; GK = Gamma Knife; NA = not available; surg = transsphenoidal or transcranial 
surgery. 
† Values represent data pertaining to both somatotroph and nonsomatotroph pituitary tumors.
‡ Median value.
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TABLE 2: Summary of previously reported case series involving SRS in patients with acromegaly (Part II)*
Authors & Year
SRS 
Unit
No. of 
Patients
Mean 
Tumor 
Vol (cm3)
Tumor 
Growth 
Control (%)
Criteria for Endocrin 
Remission§
Endocrin 
Remission 
(%)
Endocrin 
Control 
(%)¶
Adverse Effects 
(%)
Hayashi et al., 2010 GK 25 NA 100 NA NA 40** none
Iwai et al., 2010 GK 26 2.3 96 GH <2 or GH <1 after OGTT & 
 IGF-I = N
38 4 HA (4); HP (8)
Castinetti et al., 20094 GK 43 1.2 100 GH <2 or GH <1 after OGTT & 
 IGF-I = N
42 NA CNP (7)†; HP (21)†; 
 TN (2)†
Cho et al., 2009 CK 6 2.6† 92† GH <5 mIU/L 33 NA VC (8)†
Swords et al., 2009 GK 10 NA 100 GH <5 mIU/L & IGF-I = N 10 20 HP (12)†
Wan et al., 2009 GK 103 2.3–21.5 95 NA NA 37** BN (2); HP (2)†
Jagannathan et al., 2008 GK 95 2.7 98 IGF-I = N 53 NA HP (34); TLE (1); 
 VC (4)
Losa et al., 2008 GK 83 NA 98 GH <2.5 & IGF-I = N 60 21 HA (6); HP (9)
Pollock et al., 2008 GK 27 NA 100 GH <2 & IGF-I = N 67 NA HP (16)†
Tinnel et al., 2008 GK 9 NA 100 IGF-I = N 44 NA CNP (11); HP (22)
Pollock et al., 2007 GK 46 3.3‡ 100 GH <2 & IGF-I = N 50 NA BN (2); HP (33); 
 CAS (2)
Roberts et al., 2007 CK 9 2.5 100 IGF-I = N 44 12 HP (33)
Vik-Mo et al., 2007 GK 61 1.2 100 GH <2.6 mIU/L after OGTT & 
 IGF-I = N
17 NA HP (23)
Jezková et al., 2006 GK 96 2.2 100 GH <1 after OGTT & IGF-I = N 44 NA HP (27)
Voges et al., 2006 LINAC 64 3.0 97 GH <2 & IGF-I = N 37.5 47 BT (3); HP (47)†; 
 TLE (3)†; VC (1)†
Castinetti et al., 2005 GK 82 NA NA GH <2 & IGF-I = N 17 23 HP (17); TN (1); 
 VC (1)
Kajiwara et al., 2005 CK 2 11.3† 95†  NA NA NA none
Kobayashi et al., 2005 GK 67 4.4 100 GH <2 17 NA HP (15); VC (11)
Attanasio et al., 2003 GK 30 NA 100 GH <2.5 & IGF-I = N 23 17 HA (3); HP (7)
Choi et al., 2003 GK 9 1.4† 100 GH <5 mIU/L NA 50** none
Jane et al., 2003 GK 64 NA NA IGF-I = N 36 NA HP (28)
Petrovich et al., 2003 GK 6 3.7† 100 NA NA 100** HP (4)†; VC (4)†
Swords et al., 2003 LINAC 13 NA 100 GH <5 mIU/L & IGF-I = N 42 8 none
Feigl et al., 2002 GK 9 3.8† 94† NA NA NA HP (28)
Pollock et al., 2002 GK 26 4.9† 100 GH <2 & IGF-I = N 42 20 BN (5)†; HP (16)†
Ikeda et al., 2001 GK 17 NA 100 GH <1 after OGTT or IGF-I = N 82 NA none
Fukuoka et al., 2001 GK 9 4.9 100 GH <5 & IGF-I = N 40 NA none
Izawa et al., 2000 GK 29 7.1† 100 NA NA 41** BN (1)†; VC (1)†
Shin et al., 2000 GK 6 1.1 100 GH <10 mIU/L & IGF-I <450 67 NA CNP (6)
Zhang et al., 2000 GK 68 3.0 100 NA 96 NA HP (4); VC (1)
Hayashi et al., 1999 GK 22 7.3† 100 NA 41 NA HP (5); VC (5)
Inoue et al., 1999 GK 12 NA 94† NA 58 NA NA
Kim et al., 199923 GK 2 NA 100 NA 0 NA NA
Kim et al., 199924 GK 11 0.9† >68 GH <5 45.5 NA none
Laws & Vance, 1999 GK 56 NA NA IGF-I = N 25 NA NA
Mokry et al., 1999 GK 10 2.9 100 GH <7 & IGF-I <380 NA 40 HP (30)
Landolt et al., 1998 GK 16 1.9 >55 GH <10 mIU/L & IGF-I <380 70 NA none
Lim et al., 1998 GK 16 NA 92.5† GH <2 38 NA HA (36)†; HP (2)†; 
VC (2)†
Martínez et al., 1998 GK 7 4.3 100 IGF-I = N 71 NA CNP (3)†
Mitsumori et al., 1998 LINAC 1 1.9† 100 NA 100 NA HP (23)†; TLE (11)†
(continued)
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and an additional endocrinological control rate of 47% in 
their series of 64 patients with acromegaly. When more le-
nient definitions were employed, the range of hormonal re-
mission rates was 0 to 100% while rates of endocrinologi-
cal control ranged from 8% to 100% at the time of the latest 
follow-up.7–10,12,13,15,17,18,20,22–25,27,30,32,36,38–42,44,48,52,55,59–62 Using 
only a normalized IGF-I level as the criterion for hormonal 
remission, Jagannathan et al.18 reported an endocrinologi-
cal normalization rate of 53% at a mean follow-up time of 
57 months. Zhang et al.62 observed biochemical remission 
in 96% of their 68 patients, although the criteria for re-
mission are not given. Not all series, however, documented 
such impressive rates of endocrinological remission at the 
time of last follow-up. As examples, Kobayashi et al.25 and 
Castinetti et al.5 observed hormonal normalization in only 
17% of patients when they were not receiving medical ther-
apy. Such disparities likely reflect important differences in 
patient populations, adenoma characteristics, preradiosur-
gical hormonal control, and treatment regimens.
Although disagreement existed across the case se-
ries, several studies identified factors that independently 
predicted postradiosurgical endocrinological outcomes. 
Choi et al.8 found that a greater maximum radiation dose 
was associated with a higher rate of hormonal remission. 
Kim et al.24 reported a similar finding, and also discov-
ered that patients with larger tumor volumes were more 
likely to achieve biochemical remission than those with 
smaller masses. Interestingly, while the maximum radia-
tion dose significantly predicted hormonal remission in 
these studies, Kim et al.,24 Losa et al.,33 Pollock et al.,47 
and Zhang et al.62 found that the marginal radiation dose 
was not a significant prognostic factor. In addition, in 
the studies of Castinetti et al.5 and Jezková et al.,21 pre-
radiosurgical GH and IGF-I levels were found to predict 
posttreatment outcomes. Not surprisingly, those patients 
with near-normal GH or IGF-I levels were more likely to 
achieve hormonal remission than patients with markedly 
abnormal baseline values. However, Landolt et al.26 and 
Pollock et al.,46,47 identified arguably the most meaning-
ful prognostic indicator of postradiosurgical hormonal 
remission. In both series, the concomitant use of pituitary 
suppressive medications during radiosurgery was shown 
to reduce the overall rate of and increase the time to hor-
monal remission. Finally, despite a mean tumor growth 
control rate of 97% across all series, no study identified 
a significant correlation between change in adenoma size 
and eventual hormonal normalization.
Although the mean time to hormonal remission fol-
lowing adjuvant radiosurgery was not consistently report-
ed across the case series in our analysis, several studies did 
record actuarial rates of endocrinological normalization. 
In the study by Jezková et al.,21 while only 15% of patients 
achieved hormonal normalization 12 months after SRS, 
29%, 44%, and 57% of patients were found to be in re-
mission at 36, 60, and 96 months, respectively. Moreover, 
Vik-Mo et al.57 reported normal IGF-I levels in 45%, 58%, 
and 86% of patients at 36, 60, and 120 months following 
radiosurgery, respectively. Finally, although Jagannathan 
et al.18 observed an absolute remission rate of 53% with 
a mean time to remission of 30 months, a more detailed 
analysis of the data indicates that 29%, 42%, and 53% of 
patients achieved normalized IGF-I levels at 24, 48, and 
greater than 85 months after radiosurgery, respectively.
Tumor Growth Control
The rate of tumor growth control, defined as reduc-
tion or stabilization of tumor volume, ranged from more 
than 37% to 100% across all series, with an average rate 
of control of 97%. Jagannathan et al.18 reported that 92% 
of patients with adequate radiographic follow-up demon-
strated a decrease in tumor size following GKS and that 
an additional 6% showed no change in tumor volume. 
Voges et al.58 treated 64 patients with acromegaly with 
LINAC-based SRS and reported that 23% experienced a 
reduction in tumor volume while 73% had tumors that 
did not change significantly in size. To date, the largest 
series evaluating the use of the CyberKnife in the treat-
ment armamentarium of acromegaly is by Roberts et al.48 
TABLE 2: Summary of previously reported case series involving SRS in patients with acromegaly (Part II)* (continued)
Authors & Year
SRS 
Unit
No. of 
Patients
Mean 
Tumor 
Vol (cm3)
Tumor 
Growth 
Control (%)
Criteria for Endocrin 
Remission§
Endocrin 
Remission 
(%)
Endocrin 
Control 
(%)¶
Adverse Effects 
(%)
Morange-Ramos et al., 
 1998
GK 15 1.5 >37† GH <5 & IGF-I = N 20 NA HP (16)†; TN (7)
Pan et al., 1998 GK 16 1.0 100 NA 100 NA none
Witt et al., 1998 GK 20 NA 94 IGF-I = N 20 NA NA
Yoon et al., 1998 LINAC 2 NA 100 GH <5 100 NA HP (29)
Park et al., 1996 GK 7 NA 100 GH <5 57 NA none
* BN = brain necrosis; CAS = carotid artery stenosis; CNP = cranial nerve palsy; Endocrin = Endocrinological; HA = headache; HP = hypopituitarism; 
N = normal value when controlled for age and sex; OGTT = oral glucose tolerance test; TLE = temporal lobe epilepsy; TN = trigeminal neuralgia; VC = 
visual complications.
† Values represent data pertaining to both somatotroph and nonsomatotroph pituitary tumors.
‡ Median value.
§  GH in ng/ml or mIU/L (as specified); IGF-I in ng/ml.
¶ Endocrinological control indicates postradiosurgical hormonal normalization with adjuvant medical therapy.
** Percentages indicate overall rates of hormonal normalization irrespective of postradiosurgical medical therapy.
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In this study, 9 patients received CyberKnife SRS and 
none demonstrated tumor enlargement at the time of last 
follow-up. Despite these impressive statistics, the rate of 
tumor growth control did not correlate with rates of endo-
crinological remission.2,16,21,57
Adverse Effects
The overall rate of serious complications following 
radiosurgery was quite low across all series. New-on-
set anterior pituitary hormone deficiency was the most 
common adverse effect, and was noted in 0 to 47% of 
cases.2,4,5,9,13,16,18,20,21,25,32,33,38–40,44–48,54,55,57–59,61,62 Feigl et al.9 
reported a 28% incidence of hypopituitarism following 
radiosurgery, and noted that the degree of hormonal dys-
function was related to the radiation dose received by the 
pituitary stalk. However, the true incidence of SRS-in-
duced hypopituitarism is difficult to assess accurately, as 
many patients have undergone prior resection or conven-
tional fractionated radiation therapy, both of which inde-
pendently increase the likelihood of developing anterior 
pituitary hormone dysfunction. For instance, in the study 
by Jagannathan et al.,18 of the 4 patients who developed 
visual complications, 3 had received prior fractionated 
radiation therapy.
Despite the proximity of the optic apparatus to the 
pituitary gland, only 10 case series5,7,13,17,18,25,32,44,58,62  in 
our analysis reported postradiosurgical visual complica-
tions, with Kobayashi et al.25 demonstrating the highest 
incidence at 11%. The low rate of visual complications 
following SRS likely stems from each group’s attempt to 
limit the dose received by the optic apparatus to 8–10 Gy. 
Moreover, Tinnel et al.55 reported new-onset cranial nerve 
palsies in 11% of patients, although cranial neuropathies 
were only observed in 3 other studies.4,36,52 Headache, 
trigeminal neuralgia, temporal lobe epilepsy, brain ne-
crosis, and carotid artery stenosis were other documented 
complications of SRS, although these were noted rela-
tively infrequently across all series. Although none of the 
case studies were adequately powered to identify param-
eters that predict postradiosurgical complication rates, 
several groups did note that adverse effects were more 
commonly observed in patients who had received prior 
fractionated radiation therapy.18,47
Discussion
Without proper control of systemic growth levels, pa-
tients with acromegaly will follow a course of insidious 
yet progressive decline. The use of pituitary suppressive 
medications, such as somatostatin agonists or GH receptor 
antagonists, may minimize some of the metabolic sequelae 
of GH excess, but many patients are either only partially 
controlled with these therapies or become resistant after 
extended treatment periods.37 In addition, medical therapy 
is not curative and, therefore, lifelong treatment is required 
for adequate hormonal control. Current estimates demon-
strate that 75% to 90% of patients with GH overproduction 
harbor a GH-secreting pituitary adenoma, and surgical re-
moval remains the first-line treatment modality.49 Not only 
does resection remove the source of GH excess, but it also 
relieves any compression or mass effect the tumor may be 
exerting on surrounding neurovascular structures.28 Surgi-
cal extirpation is effective in inducing hormonal remission 
in more than 68% to 95% of patients with GH-secreting 
adenomas, yet a select cohort of patients develop recurrent 
acromegaly due either to regrowth of previously resected 
adenomatous tissue or to continued growth of surgically 
inaccessible tumor.28,34 Prior to the development and mod-
ernization of current radiosurgical systems, fractionated 
radiation therapy was used in the treatment algorithm for 
patients with acromegaly refractory to medical and surgi-
cal interventions. Although early reports document endo-
crinological remission following radiotherapy in more than 
60% of cases, these studies frequently employed definitions 
of remission that were more forgiving than current stan-
dards.27 Mitsumori et al.38 compared the efficacy of SRS 
and fractionated radiotherapy in the adjuvant treatment 
of hormone-secreting pituitary adenomas, and discovered 
that the overall incidence of endocrinological normaliza-
tion was roughly equal between the 2 treatment modalities. 
However, patients who received SRS achieved remission 
in 8.5 months, whereas those in whom fractionated radio-
therapy was administered did not reach hormonal normal-
ization for 18 months. Similarly, Landolt et al.27 directly 
compared GKS to traditional fractionated radiation thera-
py and found that the percentage of hormonal normaliza-
tion was roughly similar between the 2 groups, but that the 
time to remission was much shorter in the radiosurgical 
group (17 months vs 85 months, respectively). In addition 
to a more rapid normalization of hormone levels, SRS is 
also associated with a lower rate and narrower spectrum of 
adverse effects than conventional radiotherapy. In the study 
by Landolt et al.,27 16% of patients receiving fractionated 
radiotherapy developed new-onset hypopituitarism where-
as no complications were observed in the treatment arm 
that underwent SRS. Though no prospective, randomized, 
controlled trials have directly compared these two forms of 
radiation treatment, the relative safety and efficacy of SRS 
compared with traditional radiotherapy have engendered 
its use in modern clinical practice.
Although recent case series have adhered to a strict 
definition of endocrinological remission, earlier studies 
varied widely in their criteria for hormonal cure, and thus 
a large range of remission rates was observed (0 to 100%). 
At present, most groups consider the following conditions 
sufficient for endocrinological remission: 1) a random GH 
level < 2 ng/ml, or 2) a GH level < 0.5 ng/ml following an 
oral glucose challenge in addition to a normal IGF-I level 
when corrected for age and sex. Importantly, all measure-
ments must be obtained while the patient is not receiving 
pituitary suppressive medications. However, Peacey and 
Shalet43 demonstrated that GH feedback regulation was 
disrupted following radiation therapy, and therefore the 
interpretation of GH levels following radiosurgical pro-
cedures can be problematic. Moreover, given the diurnal 
and pulsatile secretion pattern of GH, it is often difficult to 
obtain accurate and true levels. On the other hand, IGF-I 
has a long half-life and stable concentration within the sys-
temic circulation.37 Because GH exerts most of its action 
through IGF-I, many neurosurgeons and endocrinologists 
have found single IGF-I measurements to faithfully repre-
sent GH activity. In fact, of the studies in our analysis in 
which a normal IGF-I level was the only criterion for hor-
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monal cure, the rates of endocrinological remission ranged 
from 20% to 71%.18,20,36,48,60 As hormonal remission rates 
following radiosurgery were noted in 17% to 82% of pa-
tients in studies in which the more stringent criteria were 
applied,2,4,5,14,16,21,33,45–47,53,54,57,58 it appears that the definition 
of endocrinological remission is of variable consequence. 
More important in the postradiosurgical assessment 
of the patient with acromegaly is the overall length of fol-
low-up. Both Jezková et al.21 and Jagannathan et al.18 ob-
served remission rates less than 30% when patients were 
evaluated 24 months after SRS. However, these rates rose 
to more than 50% when follow-up was performed for 
more than 85 months. In addition, Vik-Mo et al.57 saw 
an endocrinological remission rate of 86% at 120 months 
compared with a 45% cure rate at 36 months of follow-
up. As a result, to thoroughly assess the true efficacy of 
SRS in the management of acromegaly, patients should 
ideally receive routine endocrinological evaluations ex-
tending 84 to 120 months beyond the radiosurgical pro-
cedure. Lengthy and detailed follow-up is also necessary 
to diagnose cases of recurrent acromegaly. Jagannathan 
et al.18 reported on 3 patients who developed recurrent 
symptoms of GH excess at 36, 56, and 114 months after 
SRS. Therefore, as the latency between radiosurgery and 
hormonal cure or recurrence can be quite long, lengthy 
endocrinological and radiographic follow-up is necessary 
to determine the ultimate efficacy of SRS in acromegaly.
The use of somatostatin agonists and GH receptor an-
tagonists in the adjuvant treatment of acromegaly is com-
mon practice.35,37 However, studies by Landolt et al.26 and 
Pollock et al.46,47 demonstrated that patients who concomi-
tantly receive pituitary suppressive medications during 
radiosurgery experience lower rates of endocrinological 
normalization than those who terminate medical therapy 
more than 6 weeks prior to and 6 weeks after SRS. Al-
though the precise mechanism governing this phenomenon 
is unknown, the current belief is that the suppressive medi-
cations place the tumor cells in a quiescent state in which 
their metabolic and proliferative potential is greatly dimin-
ished. By inhibiting cell cycling, these medical therapies 
reduce the sensitivity of somatotroph cells to the effects 
of ionizing radiation during DNA synthesis.47 However, as 
no large-scale, prospective, randomized controlled trials 
have evaluated this question, it is difficult to draw defini-
tive conclusions from small observations. In fact, both Iwai 
et al.16 and Castinetti et al.4 observed that pituitary suppres-
sive medication use did not correlate with eventual hor-
monal outcome, and these differences in observation may 
be due in part to confounding factors present within each 
series. For instance, when the concurrent use of pituitary 
suppressive therapies during radiosurgery is not random-
ized, patients who require medical therapy for hormonal 
or symptomatic control are less likely to terminate the 
medication for a protracted period while those with near-
normal endocrine levels or milder symptoms will better 
tolerate the hiatus in treatment. Therefore, the difference 
in remission rates observed by Landolt et al. and Pollock et 
al. may simply reflect a more aggressive and extensive dis-
ease phenotype rather than a true effect of medical therapy. 
Nevertheless, the practice of discontinuing medical thera-
py during the radiosurgical procedure has gained clinical 
acceptance, and certain groups have adopted this strategy 
in light of these data.16 Irrespective of this controversy, pi-
tuitary suppressive medications are a critical component 
of the multimodal management algorithm for patients with 
acromegaly. For patients in whom radiosurgery is not com-
pletely curative, additional medical therapy can offer hor-
monal normalization in roughly 32% of patients, according 
to the series in our analysis.2,5,8,12,16,17,33,39,44,47,48,53,54,58,59
In addition to rates of hormonal cure of 17% to 82% 
following SRS, the mean rate of tumor growth control 
was more than 97% across the patient series (Table 2). 
Just as several studies demonstrated that endocrinological 
normalization increases with time, Mokry et al.39 reported 
that tumor volumes progressively decline following SRS. 
Nevertheless, the stabilization or reduction in adenoma 
size is not significantly associated with hormonal remis-
sion. As a result, except in cases in which the adenoma 
is compressing critical structures, tumor growth control 
is an unreliable measure of the success of SRS for the 
treatment of GH-secreting pituitary lesions. In the future, 
it will be interesting to determine whether an associa-
tion between adenoma size and hormonal cure becomes 
significant as series with larger populations and longer 
follow-up are reported.
Although surgery remains the first-line treatment for 
GH-secreting adenomas, resection of tumors that invade 
the parasellar region is fraught with difficulty.28 Because 
numerous important neurovascular structures traverse the 
cavernous sinus, SRS offers a noninvasive means of ac-
cessing this region in a potentially safe manner. However, 
exposing the cavernous sinus to a high degree of ionizing 
radiation places the structures found within it at risk for 
injury. Nevertheless, in our analysis, new-onset cranial 
neuropathies and carotid artery stenosis were infrequently 
observed following SRS. Thus, unlike the optic apparatus, 
which is especially sensitive to radiation dosing, the struc-
tures traversing the cavernous sinus appear more resistant 
to injury.50,56 Kobayashi et al.25 reported postradiosurgical 
visual complications in 11% of the 67 patients with acro-
megaly in their study, yet new-onset optic neuropathies 
were only noted in a total of 10 case series in our review of 
the literature. To minimize damage to the optic apparatus, 
many groups attempt to limit the dose it receives to 8–10 
Gy.11 In addition, inherent in the dose-planning algorithm 
is an estimation of the distance between the target tissue 
and the optic structures. While a distance of at least 5 mm 
is desired, Petrovich et al.6,44,50 demonstrated that distances 
of 1 to 2 mm are acceptable with highly conformal radia-
tion profiles. Furthermore, postradiosurgical anterior hor-
mone dysfunction was observed in 26 of the 45 case series 
in our analysis. The incidence of hypopituitarism ranged 
from 2% to 47% when reported, and the majority of this 
hypopituitarism was adequately controlled with supple-
mental medical therapy. Estimating the true incidence of 
hypopituitarism following radiosurgery, however, is diffi-
cult. Because many patients have received prior surgery or 
conventional radiotherapy, it is likely that new-onset anteri-
or hormone dysregulation results from an accumulation of 
insults rendered through numerous treatment modalities.50 
Overall, complications following SRS for the treatment of 
acromegaly are uncommon,35 and this low rate of adverse 
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effects reflects the reliability with which stereotactic radio-
surgical procedures can deliver ionizing radiation that is 
highly conformal to the target tissue.
When evaluating the efficacy and potential limitations 
of SRS, it is important to consider the duration of endocri-
nological and radiographic follow-up. Unlike surgery, SRS 
requires a protracted period of time before normalization of 
hormone levels is recognized. A similar degree of follow-
up and observation is necessary to gauge the overall safety 
of radiosurgical procedures. Jagannathan et al.18 reported 
anterior hormone deficiencies in 34% of their 95 patients 
with acromegaly following SRS for failed transsphenoidal 
operations. A detailed analysis of these cases of new-onset 
hypopituitarism, however, reveals that the incidence was 
only 5% at 12 months after radiosurgery and that more 
than 49 months of follow-up were necessary to identify the 
32 individuals with adverse effects. On the whole, despite 
a range of infrequent adverse effects, SRS is an efficacious 
component of the multimodal treatment paradigm for ac-
romegaly. Although dose selection and other treatment pa-
rameters vary depending on an array of tumor- and patient-
specific characteristics, it is our hope that future studies 
will more clearly define the optimal treatment strategy for 
acromegaly and identify the cohort of patients who will 
maximally benefit from SRS.
Conclusions
The goal of SRS in the management of GH-secreting 
pituitary lesions is to reduce hormone overproduction and 
control tumor growth while preserving normal brain tissue 
and minimizing adverse effects. In this regard, our analy-
sis of the available literature concerning the use of SRS 
in acromegaly reveals that radiosurgical procedures induce 
endocrinological remission in 17% to 82% of patients and 
leads to effective tumor growth control in 97% of cases 
when data are analyzed across all series. In addition, be-
cause SRS is capable of precisely conforming the radiation 
field to the tumor target, the overall rate of adverse effects 
is remarkably low among the series in our analysis. Over-
all, SRS represents a safe and effective treatment option for 
patients with primary or recurrent acromegaly.
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